A defect in the FANCJ/BRIP1 gene was described in 2005 to be associated with fanconi anemia (FA).
Abbreviations: aGVHD = acute GVHD; cGVHD = chronic GVHD; IPS = idiopathic pneumonia syndrome; MMRD = mismatched related donor; MRD = matched related donor; MUD = matched unrelated donor; NA = not applicable; NE = neutrophil engraftment; PE = platelet engraftment; TRM = transplant related mortality.
other populations. Here we present the outcome of four Saudi patients with FANCJ/BRIP1 subtype who underwent HSCT. All four patients presented with severe aplastic anemia with no evidence of cytogenetic abnormality, myelodysplastic syndrome or leukemia and were transfusion dependent for variable lengths of time.
Patient and transplant characteristics of the four patients are summarized in Table 1 . Supportive care was consistent for all patients. All rooms were HEPA-filtered. All blood products were leukocyte-reduced and irradiated. All patients received Pneumocystis carinii pneumonia prophylaxis. IV Ig support was provided in the first 100 days post transplant. Acyclovir prophylaxis was given to all patients starting with conditioning and continued for one year. Patients were started on broadspectrum antibiotic when their ANC dropped to o 1 × 10 9 /L. Prophylactic antifungal treatment was provided with voriconazole or caspofungin. Patients who developed positive CMV PCR received preemptive antiviral therapy with foscarnet or ganciclovir and CMV immune globulins.
The first patient (#1 Table 1 ) was conditioned with a regimen described by the Minnesota group using cord blood with slight modification. 5 The patient engrafted successfully; however, he died secondary to idiopathic pneumonia syndrome with respiratory failure that required prolonged intubation. Infectious workup was negative. McMillan et al. reported low survival and increased regimen related toxicity among patients 10 years or older, prior transfusion therapy and presence of opportunistic infection. 5 Our patient was 10 years old and had at least 2 years of transfusion before transplant, and this might have contributed to the transplant related mortality. In addition, the use of low dose TBI might have contributed to the lung toxicity in this case. Thus, we avoided radiotherapy in our subsequent unrelated transplant.
Our second patient (#2 Table 1 ) underwent 10/10 HLA-matched unrelated donor transplant and we used alemtuzumab, cyclophosphamide (40 mg/kg) and fludarabine conditioning as described previously. 6 The source of stem cells was peripheral blood that underwent TCR-alpha/beta and CD19 depletion at the collection facility to prevent GVHD. 7 The dosing of cell subtypes is shown in Table 1 . The patient had robust neutrophil and platelet engraftments and had an uneventful course and is currently more than one-year post transplant. This case showed that the combination of radiation-free/alemtuzumab-based conditioning regimen with the use of high dose CD34 and depletion of TCR-alpha/beta and CD19 is safe and effective in matched unrelated donor transplant for FA patient even in heavily transfused patient.
We used low dose cyclophosphamide (20 mg/kg) with Fludarabine and ATG in the only patient (#4 Table 1 ) who had a fully matched sibling donor. The patient received unmanipulated bone marrow, engrafted successfully and had an uneventful transplant. We increased the dose of cyclophosphamide to 40 mg/kg with similar dose of fludarabine and ATG in one child (#3 Table 1 ) who received 9/10 related transplant from the patient's mother using unmanipulated bone marrow. She engrafted successfully; however, she had severe skin and gut acute GVHD that responded to steroids and currently has no evidence of active GVHD.
Genotype-phenotype correlation in FA has been previously reported. 8 However, complementation group based transplant outcome in FA has not been thoroughly assessed given that most transplanted patients in the literature had unknown complementation group. Among FA patients who had their complementation group determined, the most frequently transplanted subtype was FANCA followed by FANCG and FANCC, and rarely FANCD1/BRCA2, FANCD2, FANCF, FANCE, FANCN, FANCP and FANCB. 5, [9] [10] [11] There is no specific FA genotype correlation with survival post transplant except for dismal outcome among FA patients with biallelic FANCD1/BRCA2 mutations given their increased risk of leukemia and solid tumors. 11 It is important to study HSCT outcome in FA based on the genotype with the goal of personalizing the conditioning protocol and supportive therapy. However, there are several limitations to achieving this, such as the heterogeneity of the mutational spectrum within each FA gene, the high prevalence of compound heterozygosity, and the presence of somatic mosaicism.
Our study was limited by the small sample size; however, we showed that FANCJ FA patients with a matched related donor could be conditioned using low dose cyclophosphamide similar to previous reports. 12, 13 We also showed that unrelated transplant in FANCJ FA can be successfully performed using non-radiation based conditioning. The use of alemtuzumab-based conditioning regimen coupled with high dose CD34 and depletion of TCR-alpha/beta and CD19 should be further studied in larger sample size in FA patients undergoing transplant from matched unrelated donor transplant. Longer follow up is needed to evaluate the risk of secondary malignancy in FANCJ patients.
